Dan Benjamin Teleman insider trades: Nasus Pharma (NSRX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Dan reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | NSRX | ↑ Buy | 6,550 | $3.10 | $20K | Direct | Jun 22, 2026 (5d) |
| Apr 22, 2026 | NSRX | ↑ Buy | 2,900 | $3.76 | $11K | Direct | Apr 22, 2026 (0d) |
| Mar 31, 2026 | NSRX | ↑ Buy | 15,000 | $2.04 | $31K | Direct | Apr 1, 2026 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Dan Benjamin Teleman's insider trades
Dan Benjamin Teleman is Chief Executive Officer at Nasus Pharma (NSRX). Since Mar 31, 2026, Dan has reported 3 open-market purchases worth $62K and no sales on SEC Form 4. In the last 12 months: 3 buys ($62K).
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NSRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.